May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Comparison of the effects of 2% carteolol and 0.5% timolol on pharmacokinetics with oral quinidine, a selective inhibitor of CYP 2D6
Author Affiliations & Notes
  • Y. Ishii
    Ophthalmology, Olympia Eye Hospital, Tokyo, Japan
    Dept of Ophthalmology,
    Oita University Faculty of Medicine, Oita, Japan
  • K. Nakamura
    Dept of Clinical Pharmacology and Therapeutics,
    Oita University Faculty of Medicine, Oita, Japan
  • Y. Inoue
    Ophthalmology, Olympia Eye Hospital, Tokyo, Japan
  • K. Nakatsuka
    Dept of Ophthalmology,
    Oita University Faculty of Medicine, Oita, Japan
  • T. Maeda
    Ophthalmology, Olympia Eye Hospital, Tokyo, Japan
  • A. Kozaki
    Ophthalmology, Olympia Eye Hospital, Tokyo, Japan
  • T. Furuya
    Ophthalmology, Olympia Eye Hospital, Tokyo, Japan
  • Footnotes
    Commercial Relationships  Y. Ishii, None; K. Nakamura, None; Y. Inoue, None; K. Nakatsuka, None; T. Maeda, None; A. Kozaki, None; T. Furuya, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2095. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Ishii, K. Nakamura, Y. Inoue, K. Nakatsuka, T. Maeda, A. Kozaki, T. Furuya; Comparison of the effects of 2% carteolol and 0.5% timolol on pharmacokinetics with oral quinidine, a selective inhibitor of CYP 2D6 . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2095.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose and Methods: Systemic adverse reactions of timolol ophthalmic solution given at usual therapeutic doses have been well documented. To evaluate the drug interaction between 0.5% timolol or 2% carteolol ophthalmic solution and the treatment of quinidine, a specific inhibitor of CYP2D6, 6 healthy Japanese male volunteers aged 21 to 28 years received 0.5% timolol or 2% carteolol ophthalmic solution with and without oral quinidine (50mg) in a randomized, Latin–square design. Results: Quinidine significantly increased the area under the plasma concentration–time curve from zero time to infinity of timolol after single instillation, P=0.0197. On the contrary, there were no significant pharmacokinetic changes after carteolol instillation under the treatment of quinidine, P>0.05. Conclusions: Quinidine did not affect the pharmacokinetics of carteolol ophthalmic solution but that of timolol ophthalmic soilution. Drug interaction related with CYP2D6 would happen in 0.5% timolol ophthalmic solution more often than 2% carteolol ophthalmic solution.

Keywords: pharmacology • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×